Showing 1651-1660 of 2050 results for "".
- MSU Researchers Discover Link Between Cholesterol and Diabetic Retinopathyhttps://modernod.com/news/msu-researchers-discover-link-between-cholesterol-and-diabetic-retinopathy/2481822/Research led by Michigan State and other universities found that diabetes, age-related health conditions, and other metabolic disorders can lead to a buildup of cholesterol in the retina. This tends to crystalize and contribute to the development of diabetic retinopathy. Cryst
- Myra Vision Announces First-in-Human Use of its Calibreye Glaucoma Drainage Devicehttps://modernod.com/news/myra-vision-announces-first-in-human-use-of-its-calibreye-glaucoma-drainage-device/2481816/Myra Vision announced it has initiated its first-in-human clinical study of the Calibreye System, a glaucoma drainage device with titratable outflow control designed to achieve optimal reduction of IOP for moderate to severe glaucoma patients. The prospective, non-randomized open-label
- Short-Term Use of Immunosuppressants for Ocular Inflammatory Diseases Not Linked to Cancer Riskhttps://modernod.com/news/short-term-use-of-immunosuppressants-for-ocular-inflammatory-diseases-not-linked-to-cancer-risk/2481793/Relatively short-term use of immunosuppressant medications to control noninfectious ocular inflammatory diseases was not associated with an increased risk of later developing cancer, according to new research led by scientists at the University of Pittsburgh and Mass Eye and Ear, a member of
- Amber Ophthalmics Announces First Patient Enrolled in Phase 2/3 Trial Evaluating Nexagon for the Treatment of PCEDhttps://modernod.com/news/amber-ophthalmics-announces-first-patient-enrolled-in-phase-23-trial-evaluating-nexagon-for-the-treatment-of-pced/2481785/Amber Ophthalmics announced that Mark S. Gorovoy, MD, has enrolled the first patient in the AMB-01-006 (NEXPEDE-1), a randomized, double-masked, vehicle-controlled phase 2/3 clinical trial designed to evaluate two concentrations of Nexagon (lufepirsen ophthalmic gel) for
- Lineage Cell Therapeutics Provides Update on OpRegenhttps://modernod.com/news/lineage-cell-therapeutics-provides-update-on-opregen/2481775/Lineage Cell Therapeutics provided an update on its progress with OpRegen (RG6501), its product candidate for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Lineage stated that it continues to execute its
- American Academy of Optometry Announces 2023 Award Recipientshttps://modernod.com/news/american-academy-of-optometry-announces-2023-award-recipients/2481760/The American Academy of Optometry (AAO) announced the recipients of the 2023 AAO awards recognizing distinguished individuals who have made important contributions to advancing the profession of optometry. The awards will be presented during ceremonies at Academy 2023 New Orleans,
- Smartlens Closes $6.1 Million Series A Financing to Advance miLens Devicehttps://modernod.com/news/smartlens-closes-61-million-series-a-financing-to-advance-milens/2481727/Smartlens has closed an oversubscribed $6.1 million Series A equity financing round to advance regulatory clearance for miLens, a novel, electronics-free, soft contact lens for monitoring diurnal IOP. The miLens device is an electronics free soft contact lens that uses mi
- Bausch + Lomb Acquires Blink OTC Eye Drops from J&J Visionhttps://modernod.com/news/bausch-lomb-acquires-blink-eye-drops-from-jj-vision/2481709/The latest in a string of major moves by Bausch + Lomb, the company announced it is purchasing the Blink product line of eye and contact lens
- MediPrint Ophthalmics Announces Results from its SIGHT-2 Phase 2b Group 1 Clinical Studyhttps://modernod.com/news/mediprint-ophthalmics-announces-results-from-its-sight-2-phase-2b-group-1-clinical-study/2481665/MediPrint Ophthalmics announced it has completed its SIGHT-2 dose-finding phase 2b Group 1 (low dose) study for its proprietary drug-eluting contact lens for glaucoma. This is the first of potentially three doses in the second study of its clinical program SIGHT (Sustained Innovati
- Gamesquare Partners with Vivior to Help Gamers Build Healthy Screen Habitshttps://modernod.com/news/gamesquare-partners-with-vivior-to-help-gamers-build-healthy-screen-habits/2481646/GameSquare Holdings announced a multi-year, multi-million dollar partnership with Swiss vision care startup Vivior with the aim of promoting healthy digital habits, according to a company news release. Through content creation, product development, and competition, GameSquare and Vivior